Annovis Bio, Inc. announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer's disease (AD). A total of 327 patients have successfully concluded the phase II/III trial out of the initial 353 enrolled.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.72 USD | +4.31% | +80.91% | -53.37% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.37% | 92.05M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease